Status:
COMPLETED
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
Lead Sponsor:
Amgen
Conditions:
Crohn Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to investigate the effects of an investigational medication, called CCX282-B, on safety and on the some of the symptoms of Crohn's Disease in patients who are exp...
Detailed Description
CCX282-B is being developed as a treatment for inflammatory bowel diseases such as Crohn's Disease. CCX282-B is a highly potent, orally active, chemokine receptor antagonist whose single target is the...
Eligibility Criteria
Inclusion
- Diagnosis of moderate to severe Crohn's Disease in small intestine; disease must be active at the time of study entry
- Use of adequate and approved methods of birth control throughout the study period
- Willing and able to sign an informed consent
Exclusion
- Pregnant or breastfeeding
- Infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV; the virus that causes AIDS)
- Abuse of alcohol or of illegal drugs
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00102921
Start Date
August 1 2004
End Date
December 1 2005
Last Update
March 6 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
2
Rocky Mountain Clincal Research
Golden, Colorado, United States, 80104
3
Arapahoe Gastroenterology
Littleton, Colorado, United States, 80120
4
Atlanta Gastroenterology Associates
Atlanta, Georgia, United States, 30342